VX 118
Alternative Names: VX-118Latest Information Update: 10 Jun 2024
At a glance
- Originator Vertex Pharmaceuticals
- Class Antifibrotics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cystic fibrosis
Most Recent Events
- 04 May 2024 Vertex Pharmaceuticals completes phase I clinical trials in Cystic fibrosis (In volunteers) in USA (PO) (NCT06312787)
- 02 Apr 2024 Phase-I clinical trials in Cystic fibrosis (In volunteers) in USA (PO) (NCT06312787)
- 22 Mar 2024 Preclinical trials in Cystic fibrosis in USA (PO) (Vertex Pharmaceuticals pipeline, March 2024)